And this is only Cohort 1 on the lowest dosage!
It will be interesting to see the results of Cohort 3 (the same people in Cohort 1) to see if the higher dosage provides any marked difference.
No wonder all of the participants wanted to remain on MPL and move up to a higher dosage/cohort!
Absolutely fantastic news for each of the participants and their families.
I really hope that the MND progression is slowed to the point where people can maintain a lot longer quality of life.
Ann: Results show MPL suppresses biomarkers associated with MND, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.005(3.23%) |
Mkt cap ! $78.76M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 16.0¢ | 15.5¢ | $56.89K | 366.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34020 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 35019 | 1 |
View Market Depth
| Last trade - 15.56pm 18/07/2025 (20 minute delay) ? |
| NUZ (ASX) Chart |